MT-CYB: Cytochrome b
Protein in Plasmodium falciparum that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on MT-CYB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Atovaquone | Approved | GSK | Small molecule | InhibitorCytochrome b inhibitor | 4 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Atovaquone | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | Nov 5, 2026 |
| Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives) | Atovaquone | Phase 4 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | Jan 21, 2026 |
| Atovaquone Combined With Radiation in Children With Malignant Brain Tumors | Atovaquone | Phase 1 | Recruiting | Emory University | Oct 3, 2024 |
| Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | Atovaquone | Phase 2 | Recruiting | Emory University | Aug 18, 2023 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1777, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets